Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Crescent Biopharma, Inc.
NASDAQ:CBIO
Intrinsic Alpha fair value
Locked
Current Price
$12.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +424.9% | +67.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +424.9% over three years. Forward estimates point to Revenue at +67.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Arcus Biosciences, Inc. NYSE:RCUS | $2.51B | $17.43 | Not rated | -8.2 | -21.94% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | $28.83 | Not rated | -7.8 | +7.70% |
Zymeworks Inc. NASDAQ:ZYME | $1.83B | $26.24 | Not rated | -16.6 | +13.27% |
CytomX Therapeutics, Inc. NASDAQ:CTMX | $444.73M | $2.04 | Not rated | -8.8 | -48.63% |
Compugen Ltd. NASDAQ:CGEN | $198.92M | $2.10 | Undervalued | 5.4 | +20.99% |
Veraxa Biotech Holding AG NASDAQ:VRXA | $156.96M | $1.11 | Not rated | — | — |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +27.92% |
Compass Therapeutics, Inc. NASDAQ:CMPX | $139.35M | $0.77 | Not rated | -5.5 | -87.61% |
NovaBridge Biosciences NASDAQ:NBP | $42.59M | $0.85 | Not rated | -25.5 | -80.11% |
Context Therapeutics Inc. NASDAQ:CNTX | $16.61M | $0.18 | Not rated | -1.5 | -35.83% |
Continue the stock analysis
Jump to another research area for this company.